Peter Hofland

Eager to report about Changing Strategies in the ‘War on Cancer’ @OncoZine, @ADCReview | Journal of Antibody-drug Conjugates and The Onco’Zine Brief.

[Bio99 @BIO99_BIO99]

$NWBO Exciting to hear!!

[ASCO @ASCO]

Don't miss out on the only global GI meeting with dedicated multidisciplinary committees and faculty. Attend ASCO's #GI24. Discounts ending 12/13.

[SABCS @SABCSSanAntonio]

Clinical science workshops at #SABCS23 will cover topics including tumor agnostic trials, tumor boards, and clinical case discussions. Pedram Razavi, MD, PhD, shares a preview in SABCS Meeting News:
https://t.co/0cAenr9J4b
#BCSM

[Paolo Tarantino @PTarantinoMD]

Yes, it is important to focus on the differential activity of capi to understand the FDA decision

- Adding capi in pathway-altered: PFS HR 0.50, delta 4.2 months

- Adding capi in pathway non-altered (supplementary files in the NEJM publication): PFS HR 0.79, delta 1.6 months

[Nancy Lin, MD @nlinmd]

Nice work from @KeithLigon5 and @SantagataLab surveying primary brain tumors for ADC targets

Most tumors: HER3, B7-H3, NECTIN4. Ependymomas: HER2
Meningiomas: weak-mod HER2
ACP and PCP: B7-H3; TROP2 in whorled ACP epithelium
AT/RT: CLDN6
Great roadmap for clinical trials!

[Nancy Lin, MD @nlinmd]

Great talk from Dr Matthias Preusser on the emerging role of ADCs in pts with brain metastases. Ongoing studies with T-DXd, Dato-DXD, and Patritumab-DXd!

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Dr. Afshin Dowlati with results from TROPiCS-03 #SCLC cohort with 2L sacituzumab govitecan (TROP2 ADC). cRR 37% with mDOR 6.3m, 63% of responses ongoing at 6m. AEs include diarrhea (mostly G1/2) and neutropenia (33% G3) but no discontinuations due to AE.

[Tom Powles @tompowles1]

Stopping axitinib after 9 months of axititinib/avelumab in RCC shows median duration of time to progression is only 4 months off therapy #ESMO23 . That’s short and suggests it’s too early to stop? The timing of discontinuation of of therapy in RCC is a key issue. @DrIacovelli

[Ramy Sedhom, MD, FASCO @ramsedhom]

Wonderful to see advances in cancer treatment at #ESMO23

Hearing @OtisBrawley speak this morning is a friendly reminder the best thing we can do for our patients is to REDUCE THE RISK of cancer

As oncologists, let's advocate for improved public health. The risk of poor diet/exercise is almost as great as smoking!

[Sumanta K. Pal, MD, FASCO @montypal]

Eloquent discussion from @apolo_andrea @theNCI synthesizing data from #EV302 & #CM901. Loved the fact that she offered a strong, definitive opinion on the "winner" in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP? #ESMO23

[Sara Tolaney @stolaney1]

TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo

63% w/1L prior chemo
~80% w/prior cdk 4/6i

PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001
ORR 36.4% vs 22.9%

Fewer grade >=3 AEs w/Dato-DXd c/w TPC
50% Stomatitis,3% ILD

@OncoAlert #bcsm #ESMO23 @dradityabardia

[Paolo Tarantino @PTarantinoMD]

Elegant discussion by S. Chandarlapaty. Clear PFS benefit of Dato-DXd over chemo in MBC & NSCLC, with reasonable, but non-benign toxicity profile (eg 2% of G5 ILD in TL01). Efficacy after other Topo1 ADCs uncertain. Translational efforts warranted to unlock the potential of ADCs.

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

1. ADC trials in ER+ HER2 'neg' MBC differ by HER2 status and lines of prior therapy
2. DB04 >TropionB01 >Tropics (cf. control PFS)
3. > 50% are HER2 'low'
4. TDxD has best HR, RR, and goes first
5. No data that ADC post ADC offers meaningful benefit compared to std chemo

[Peter Hofland @PeterHofland11]

@DrSGraff @BarbaraPistill2 @OncoAlert @myESMO With new and exciting updates about Antibody-drug Conjugates (ADCs) presented at @myESMO / #ESMO2023 / #ESMO23 see our reporting, at https://t.co/lU8uPMZuFP. And for an overview of ADC in past and current (clinical) development go to the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

With new and exciting updates about Antibody-drug Conjugates (ADCs) presented at @myESMO / #ESMO2023 / #ESMO23 see our reporting, at https://t.co/lU8uPMZuFP. And for an overview of ADC in past and current (clinical) development go to the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

@PTarantinoMD With new and exciting updates about Antibody-drug Conjugates (ADCs) presented at @myESMO / #ESMO2023 / #ESMO23 see our reporting, at https://t.co/lU8uPMZuFP. And for an overview of ADC in past and current (clinical) development go to the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

@raffcolo With new and exciting updates about Antibody-drug Conjugates (ADCs) presented at @myESMO / #ESMO2023 / #ESMO23 see our reporting, at https://t.co/lU8uPMZuFP. And for an overview of ADC in past and current (clinical) development go to the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

@PTarantinoMD With new and exciting updates about Antibody-drug Conjugates (ADCs) presented at @myESMO / #ESMO2023 / #ESMO23 see our reporting, at https://t.co/lU8uPMZuFP. And for an overview of ADC in past and current (clinical) development go to the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

@ERPlimackMD @tompowles1 @apolo_andrea @DrChoueiri @montypal @TiansterZhang @PGrivasMDPhD @BladderCancerUS @myESMO With new and exciting updates of Antibody-drug Conjugates presented at @myESMO in #Madrid this year, see, for an overview of ADC in past and current (clinical) development the ADC drug map at https://t.co/g8BBuoOLuu

[Peter Hofland @PeterHofland11]

@hoperugo @OncoAlert With new and exciting updates of Antibody-drug Conjugates presented at @myESMO in #Madrid this year, see, for an overview of ADC in past and current (clinical) development the ADC drug map at https://t.co/g8BBuoOLuu